跳至主要内容
临床试验/EUCTR2012-005337-37-IT
EUCTR2012-005337-37-IT进行中(未招募)不适用

ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE

Istituto Clinico Humanitas0 个研究点开始时间: 2013年3月14日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1)Female subjects, aged <40yr at the time of breast cancer diagnosis
  • 2)Diagnosis of operable breast cancer any T and N, any ER
  • 3)Patients candidate to adjuvant chemotherapy for 4-8 cycles.
  • 4)Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 28 days prior to the start of the study treatment.
  • 5)Negative pregnancy test at the study enrolment; fertile women must use effective contraception during chemotherapy
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1)Presence of distant metastasis
  • 2)Clinically significant cardiovascular disease
  • 3)Psychological or social conditions which might affect study compliance
  • 4)Unstable neurologic function
  • e)Patients with known allergy to any of the components of the study medication
  • 5)Pregnancy or lactation

研究者

发起方
Istituto Clinico Humanitas

相似试验